AIM ImmunoTech (FRA:HXB2) Total Assets : €17.77 Mil (As of Dec. 2023)

View and export this data going back to . Start your Free Trial

What is AIM ImmunoTech Total Assets?

AIM ImmunoTech's Total Assets for the quarter that ended in Dec. 2023 was €17.77 Mil.

During the past 12 months, AIM ImmunoTech's average Total Assets Growth Rate was 0.20% per year. During the past 3 years, the average Total Assets Growth Rate was -37.30% per year. During the past 5 years, the average Total Assets Growth Rate was -16.10% per year. During the past 10 years, the average Total Assets Growth Rate was -5.90% per year.

During the past 13 years, AIM ImmunoTech's highest 3-Year average Total Assets Growth Rate was 48.50%. The lowest was -37.30%. And the median was -0.65%.

Total Assets is connected with ROA %. AIM ImmunoTech's annualized ROA % for the quarter that ended in Dec. 2023 was -210.26%. Total Assets is also linked to Revenue through Asset Turnover. AIM ImmunoTech's Asset Turnover for the quarter that ended in Dec. 2023 was 0.00.

AIM ImmunoTech Total Assets Historical Data

The historical data trend for AIM ImmunoTech's Total Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

AIM ImmunoTech Total Assets Chart

AIM ImmunoTech Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Assets

Get a 7-Day Free Trial

18.68

53.09

51.06

38.22

17.77

AIM ImmunoTech Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Total Assets	Get a 7-Day Free Trial															38.22	34.99	31.03	26.11	17.77

AIM ImmunoTech Total Assets Calculation

Total Assets are all the assets a company owns.

From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.

AIM ImmunoTech's Total Assets for the fiscal year that ended in Dec. 2023 is calculated as

Total Assets	=	Total Equity (A: Dec. 2023 )	+	Total Liabilities (A: Dec. 2023 )
	=	9.385	+	8.388
	=	17.77

AIM ImmunoTech's Total Assets for the quarter that ended in Dec. 2023 is calculated as

Total Assets	=	Total Equity (Q: Dec. 2023 )	+	Total Liabilities (Q: Dec. 2023 )
	=	9.385	+	8.388
	=	17.77

AIM ImmunoTech (FRA:HXB2) Total Assets Explanation

Total Assets is connected with ROA %.

AIM ImmunoTech's annualized ROA % for the quarter that ended in Dec. 2023 is

ROA %	=	Net Income (Q: Dec. 2023 )	/	( (Total Assets (Q: Sep. 2023 )	+	Total Assets (Q: Dec. 2023 ))	/ count )
	=	-46.128	/	( (26.106	+	17.772)	/ 2 )
	=	-46.128	/	21.939
	=	-210.26 %

Note: The Net Income data used here is four times the quarterly (Dec. 2023) data.

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Total Assets is linked to total revenue through Asset Turnover.

AIM ImmunoTech's Asset Turnover for the quarter that ended in Dec. 2023 is

	Asset Turnover
=	Revenue (Q: Dec. 2023 )	/	( (Total Assets (Q: Sep. 2023 )	+	Total Assets (Q: Dec. 2023 ))	/ count )
=	0.06	/	( (26.106	+	17.772)	/ 2 )
=	0.06	/	21.939
=	0.00

Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.

AIM ImmunoTech Total Assets Related Terms

Thank you for viewing the detailed overview of AIM ImmunoTech's Total Assets provided by GuruFocus.com. Please click on the following links to see related term pages.

AIM ImmunoTech (FRA:HXB2) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » AIM ImmunoTech Inc (FRA:HXB2) » Definitions » Total Assets

Comparable Companies

Traded in Other Exchanges

AIM:USA

Address

2117 SW Highway 484, Ocala, FL, USA, 34473

Website

https://www.aimimmuno.com

AIM ImmunoTech Inc is an immuno-pharma company focused on research and development of therapeutics to treat immune disorders, viral and cancer diseases. AIM's flagship products include Ampligen (Rintatolimod), a drug of large macromolecular RNA molecules for cancer and viral diseases and drug Alferon N Injection for a category of STD infection. Clinical trials of Ampligen include studies of cancer patients with renal cell carcinoma, malignant melanoma, colorectal cancer, advanced recurrent ovarian cancer and triple negative metastatic breast cancer. The company is also advancing Ampligen as a potential treatment for COVID-19. FDA has authorized the first human trial assessing the safety and effectiveness of Ampligen in combination with interferon alfa-2b, in cancer patients with COVID-19.

AIM ImmunoTech (FRA:HXB2) Headlines

No Headlines